{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 22 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'The decision to withdraw from trial treatment or from the whole trial as well as the reason', 'must be documented in the patient files and CRF (case record form).', 'In the event a patient or partner of a patient has become pregnant prior to withdrawal from', 'the trial, the procedures in Section 5.2.6.1 should be followed. If a patient becomes pregnant', 'during the trial, the prescribing physician should be notified and continuation of nintedanib', 'treatment addressed by the prescribing physician. Continued participation in the trial should', 'be discussed with the clinical monitor.', '3.3.4.1', 'Withdrawal from trial treatment', 'An individual patient is to be withdrawn from trial treatment if:', 'The patient wants to withdraw from trial treatment, without the need to justify the', 'decision.', 'The patient needs to take concomitant treatments that interfere with the required OFEV', 'treatment.', 'The patient can no longer be treated with trial procedures for other medical reasons (such', 'as surgery, adverse events, other diseases, or pregnancy).', 'The patient has repeatedly shown to be non-compliant with important trial procedures', 'and, in the opinion of both, the investigator and sponsor representative, is not willing or', 'able to comply with the trial requirements in the future.', \"Given the patient's agreement, the patient will undergo the procedures for early treatment\", 'discontinuation and follow up as outlined in the Flow Chart (FC) and section 6.2.3.', 'For all patients the reason for withdrawal from trial treatment (e.g. adverse events) must be', 'recorded in the CRF. These data will be included in the trial database and reported.', '3.3.4.2', 'Withdrawal of consent for trial participation', 'Patients may withdraw their consent for trial participation at any time without the need to', 'justify the decision.', 'This will however mean that no further information may be collected for the purpose of the', 'trial and negative implications for the scientific value may be the consequence. Furthermore', 'it may mean that further patient follow up on safety cannot occur.', 'If a patient wants to withdraw consent, the investigator should explain the difference between', 'treatment withdrawal and withdrawal of consent for trial participation and explain the options', 'for continued follow up after withdrawal from trial treatment, please see section 3.3.4.1', 'above.', '3.3.4.3', 'Discontinuation of the trial by the sponsor', 'Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial', 'site at any time for the following reasons:', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 23 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '1. Failure to meet expected enrolment goals overall or at a particular trial site', '2. Emergence of any efficacy/safety information invalidating the earlier positive benefit-', 'risk-assessment that could significantly affect the continuation of the trial', '3. Violation of GCP, the trial protocol, or the contract impairing the appropriate conduct of', 'the trial', 'The investigator / the trial site will be reimbursed for reasonable expenses incurred in case of', 'trial termination (except in case of the third reason).', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}